Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Net Margin (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Net Margin data on record, last reported at 89575.0% in Q4 2025.

  • For Q4 2025, Net Margin rose 2009306.0% year-over-year to 89575.0%; the TTM value through Dec 2025 reached 481.23%, up 8864493.0%, while the annual FY2025 figure was 481.23%, 8880189.0% up from the prior year.
  • Net Margin reached 89575.0% in Q4 2025 per VRDN's latest filing, down from 49.68% in the prior quarter.
  • Across five years, Net Margin topped out at 49.68% in Q3 2025 and bottomed at 134313.33% in Q2 2025.
  • Average Net Margin over 5 years is 54929.62%, with a median of 66806.94% recorded in 2023.
  • Peak YoY movement for Net Margin: tumbled -6495647bps in 2023, then skyrocketed 8909451bps in 2025.
  • A 5-year view of Net Margin shows it stood at 13526.17% in 2021, then crashed by -222bps to 43604.76% in 2022, then plummeted by -112bps to 92593.06% in 2023, then dropped by -18bps to 109668.06% in 2024, then grew by 18bps to 89575.0% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 89575.0% in Q4 2025, 49.68% in Q3 2025, and 134313.33% in Q2 2025.